Mutations in Young Patients With Aortic Disease

Genetic Features
The probands of all 80 probands were investigated for FBN1, TGFBR1, or TGFBR2 mutations. If we could find no mutations in these genes, COL3A1, MYH11, SLC2A10 and ACTA2 mutations were selectively examined according to the clinical findings of each patient. A flow diagram of the investigations is shown in Figure 1 .
FBN1, TGFBR1, TGFBR2, ACTA2, and SLC2A10 mutations were examined using genomic DNA, which was isolated from the peripheral blood leukocytes of patients and amplified using polymerase chain reaction as described previously. 5 Genetic variants were screened with a denaturing high performance liquid chromatography method and the detected variations were further confirmed using direct sequencing as described previously. 1,2,5,8 COL3A1 and MYH11 mutations were examined using mRNA, which was obtained from surgical tissue specimens. Therefore, we could not determine the existence of COL3A1 and MYH11 mutations if the surgical specimen could not be obtained.
Clinical Features Related to the Ghent Nosology
In order to determine whether the patients fulfilled the diagnostic criteria of MFS using the Ghent nosology, all patients received careful assessments, including physical examination, computed tomography scanning or magnetic resonance imaging, echocardiography, and slit-lamp examination for ocular lesion, which covered all criteria listed in the Ghent nosology. 8 We defined the patients who fulfilled the Ghent nosology as the "definite MFS group", and the rest as "nondefinite MFS group". According to the results of these examinations, all 80 probands were divided into definite MFS group (n=51) and non-definite MFS group (n=29).
Comparison of Probands in the Definite MFS Group and the Non-Definite MFS Group
First, clinical features were compared between the definite and non-definite MFS groups with respect to: (1) age, gender, height; (2) family history of aortic dissection or sudden death at age <50 years, or family history of suspected MFS; (3) Figure 1 . Genetic mutations of FBN1, TGFBR1, or TGFBR2 were investigated for all 80 patients suspected of having connective tissue disorders. If no mutations could be found in these genes, COL3A1, MYH11, SLC2A10 and ACTA2 mutations were selectively examined according to the clinical findings. MFS, Marfan syndrome.
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Ghent nosology. Ghent nosology included: involvement of skeletal system such as arm-span-to-height ratio, thumb and wrist signs, and joint hypermobility; involvements of the cardiovascular system, such as AAE, aortic dissection or mitral valve prolapse; ectopia lentis; dural ectasia; involvement of the pulmonary system, such as pneumothorax and apical blebs in the apex; and involvement of skin system, such as atrophic striae and recurrent hernia. Second, the genetic features were compared between the 2 groups (Figure 2) .
Specific Clinical Features in the Non-Definite MFS Group
We divided the non-definite MFS group into 2 groups, the patients with some mutations in FBN1, TGFBR1 or TGFBR2, ACTA2, MYH11, SLC2A10, or COL3A1 (Mutation (+) group) and the patients without these mutations (Mutation (-) group). Then, we investigated specific clinical features in each group, which were the characteristics of connective tissue disorders other than MFS, such as Loeys-Dietz syndrome (LDS), Ehlers-Danlos syndrome type IV, arterial tortuosity syndrome (ATS), and thoracic aortic aneurysm and/or aortic dissection (TAAD). The following specific features of each disease were examined: hyperterolism; bifid uvula; aortic branch aneurysms; squint (which were often seen in LDS); easy bruising; thin and visible veins, (which were often seen in Ehelers-Danlos syndrome type IV); arterial tortuosity (which were often seen in LDS or ATS); livedo reticularis; iris flocculi (which were often seen in patients with ACTA2 mutation); and patent ductus arteriosus (LDS and patients with MYH11 mutations). 4,6,9-12 In addition to comparing the phenotypes of patients with non-definite MFS with the definite MFS group, we examined how the patients in non-definite MFS group fulfilled each feature of Ghent criteria.
Ethical Considerations
The present study was conducted according to the articles of the Declaration of Helsinki regarding the participation of human subjects in clinical studies and was approved by the Ethics Committee of the National Cardiovascular Center (Suita, Japan). All patients gave written informed consent to participate in the present study.
Statistical Analysis
Continuous variables were expressed as mean ± standard deviation (SD). The Student t-test was used to analyze significant differences in factors between the 2 groups. Differences in percentages between the 2 groups were evaluated using Fisher's exact test. SPSS (11.0) software (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses. A P value<0.05 was considered statistically significant.
Results
Genetic Features of Patients
For all 80 probands, mutations of FBN1, TGFBR1, and TGFBR2 were investigated. Mutations of FBN1, TGFBR1, and TGFBR2 were found in 48 (60%), 2 (3%), and 4 (5%) of the probands, respectively. At the next step, COL3A1, MYH11, SLC2A10, and ACTA2 mutations were selectively examined according to the clinical features among the 26 probands who did not have any mutations in FBN1, TGFBR1, 
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and TGFBR2. Mutations of ACTA2 were examined in all of these 26 probands and 4 mutations were found. Mutations of SLC2A10 were not found in 24 probands examined, and there were no COL3A1 mutations out of 9 examined, and no MYH11 mutations out of 8 examined. As a result, at least 58 (73%) mutations among all 80 probands were associated with aortic disease in young adults. The investigation flow chart is shown in Figure 1 .
The results of genetic analysis of FBN1 did not indicate any apparent phonotype-genotype correlation. All mutations of TGFBR1 or TGFBR2 were found in the exons corresponding to the kinase domain (data not shown). Also, all of these TGFBR1 or TGFBR2 mutations but one were a missense mutations, while the nonsense mutations found were not suggested to be a mutation causing nonsense mediated mRNA decay (data not shown).
Comparison of the Probands in Definite and Non-Definite MFS Groups
Genotypic Manifestations Genotypic manifestations in each group are shown in Table 1 . Among 51 probands in the definite MFS group, 47 (92%) FBN1 mutations and 1 (2%) TGFBR2 mutations were found. ACTA2 and SLC2A10 mutations were investigated in the remaining 3 probands in the definite MFS group and no mutations were found.
Among 29 probands in the non-definite MFS group, 1 (3%) FBN1, 2 (7%) TGFBR1, and 3 (10%) TGFBR2 mutations were found. In the remaining 23 probands, 4 ACTA2 mutations were found. In total, at least 10 out of 29 (34%) probands in the non-definite MFS group had genetic mutations. Genetic mutations of both groups are summarized in Figure 3 .
Comparing the probands in the definite and non-definite MFS groups, FBN1 mutations were found more frequently in the definite MFS group than in non-definite MFS group (92% vs 3%, P<0.01). In contrast, TGFBR1 or TGFBR2 mutations were found more frequently in the non-definite than in the definite MFS group (17% vs 2%, P<0.05). ACTA2 mutations were only found in the non-definite MFS group.
Phenotypic Manifestations The baseline clinical features are shown in Table 2 . Comparing the probands in the definite and non-definite MFS groups, shorter height was observed more frequently in the non-definite MFS group (male; 176± 6 cm vs 184±6 cm, P<0.01, female; 159±3 cm vs 174±8 cm, 
Undetermined (n, %) 3/51 (6%) 19/29 (66%)** Data were expressed as mean ± SD. *P<0.05, **P<0.01. AKUTSU K et al.
P<0.01).
In the non-definite MFS group, the height of the patients with genetic mutations (n=10) was not significantly different from those without genetic mutations (n=19) (male; 177±6 cm vs 176±6 cm, female; 158±2 cm vs 159±3 cm). Obstructive sleep apnea was observed in 2 probands (2%) in the definite MFS group and 3 probands (13%) in the non-definite MFS group. Out of 3 probands with obstructive sleep apnea in the non-definite MFS group, one was associated with ACTA2 mutations. Two probands in the definite MFS group and 1 proband in the non-definite MFS group presented with aortic diseases during pregnancy, and the latter proband had ACTA2 mutations. Probands with hypertension from young age, and steroid use were not observed in either group. Although the number of the patients with family history of MFS or aortic disease did not differ between the definite and non-definite MFS group, some patients in the non-definite MFS group with no genetic mutations identified had a family history of MFS (4 out of 19; 21%). Clinical features related to Ghent nosology are shown in Table 3 . The following manifestations of Ghent nosology were less frequent in the non-definite than in the definite MFS group: skeletal system involvement (7% vs 82%, P< 0.01); thumb sign and wrist sign (3% vs 20%, P<0.01); joint hypermobility (12% vs 52%, P<0.01); AAE (52% vs 100%, P<0.01); mitral valve prolapse (17% vs 52%, P<0.01); ectopia lentis (0% vs 26%, P<0.01); dural ectasia (14% vs 69%, P<0.01); and skin involvement (7% vs 24%, P<0.01). The genetic background of each skeletal manifestation is also shown in Table 3 . In the non-definite MFS group, Ghent skeletal manifestations were seen in some probands. However, one particular proband with mutations in TGFBR2 gene fulfilled the criteria of "skeletal involvement", which means fulfilling 4 major skeletal manifestations, "arm-spanto-height ratio >1.05", "thumb sign and wrist sign", and "joint hypermobility", while the other probands of this group who fulfilled the skeletal criterion were not found to have any genetic mutations.
Clinical Features in Non-Definite MFS Group
The specific clinical features of the patients in the non-defi- Data were expressed as mean ± SD. **P<0.01 Skeletal involvement: fulfilling 2 major criteria of Ghent nosology or one major and 2 minor criteria.
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nite MFS group are shown in Table 4 . Since easy bruising and thin and visible veins were not observed in the patients in the present study, no patient was strongly suspected of having Ehlers-Danlos syndrome. Patent ductus arteriosus was also not observed. Few specific skeletal features were observed in the patients with ACTA2 mutations. In the Mutation (-) group, only 2 patients with tortuous aorta and one patient with squint, both without family history of MFS or aortic disease, were observed. In addition, the extent of fulfilling the Ghent nosology in the non-definite MFS group is shown in Table 4 . In the Mutation (+) group, some patients with TGFBR1 or TGFBR2 mutations fulfilled some criteria. In contrast, only one patient with ACTA2 mutations fulfilled the criterion of skin involvement in addition to major criteria of cardiovascular system. In the Mutation (-) group, few patients fulfilled the Ghent criteria, even though some had a family history of MFS or aortic disease
Discussion
The results of the present study demonstrated that genetic mutations account for at least three-fourths of all causes of aortic disease in young adults. Especially in the non-definite MFS group, the genetic examination elucidated mutations of TGFBR1 or TGFBR2 and ACTA2 in some probands, and genetic mutations accounted for at least one-third of all causes of aortic disease in the probands of the non-definite MFS group.
Among young patients with aortic disease, MFS associated with FBN1 mutations was the most frequent cause of aortic disease. Recently, genetic mutations other than FBN1 mutations were found in aortic disease. TGFBR1 or TGFBR2 mutations are known to cause LDS, Furlong syndrome and Shprintzen-Goldberg syndrome. 9,13,14 Among these diseases, phenotypic data of LDS are well documentd. 9 LDS is characterized by widely spaced eyes (hypertelorism), bifid uvula and/or cleft palate, and generalized arterial tortuosity with ascending aortic aneurysm and dissection. Although LDS was reported as MFS II initially, the phenotypic manifestations are often different from MFS. 2 In addition, the patients with TGFBR1 or TGFBR2 mutations do not always show the typical phenotype of LDS. 15 Therefore, we could not easily discriminate LDS from normal individuals only by clinical features.
ACTA2 mutations are reportedly the most common cause of TAAD without syndromatic characteristics, and they are responsible for 14% of TAAD, as compared with 5% and <2% for TGFBR2 and MYH11, respectively. 4,16, 17 The clinical features of the patients with ACTA2 mutations were reported to be livedo reticularis and iris flocculi, but they are not always found in these patients, as we recently reported for a number of probands with ACTA2 mutations. 4,5 SLC2A10 mutations cause ATS, which is characterized by tortuousity and elongation of the large and medium-sized arteries, pulmonary arteries stenosis and aneurysm formation, often resulting in death at young age. 11 MYH11 mutations are known as a cause of TAAD with patent ductus arteriosus. 6 Although patients AKUTSU K et al.
with mutations of ACTA2, SLC2A10 or MYH11 will develop characteristic abnormality in the aorta, their characteristic MFS-like features have not been described; therefore, we could not recognize their genetic disease by their readily observable physical features. In the present study, FBN1 mutations were found in 48 of 80 (60%) probands from patients with suspected connective tissue disorders, who had aortic diseases at a young age, and TGFBR1 or TGFBR2 mutations were found in 6 (8%) probands. ACTA2 mutations were detected in 4 of the 26 probands examined. In total, more than 58 (73%) young probands with aortic disease had genetic mutations. Among 29 probands in the non-definite MFS group, there was 1 (3%) FBN1 mutations and 5 (17%) TGFBR1 or TGFBR2 mutations. ACTA2 mutations were found in 4 of the 22 probands examined. In total, more than 10 probands in the non-definite MFS group had genetic mutations. The remainder of the patients may have unknown genetic mutations, acquired factors or both. Indeed, some patients in the non-definite MFS group with no genetic mutations identified in the present study had a family history of MFS or aortic disease.
Acquired factors causing aortic diseases have not been fully elucidated. The causes of aortic dissection and those of aortic aneurysm should be different, and the causes of aortic disease in young individuals and those in old individuals should be also different. In elder individuals, aortic diseases were often associated with hypertension, smoking, atherosclerosis, and sleep apnea syndrome. 18-21 In contrast, in young individuals, the acquired factors causing aortic diseases are slightly different, including hypertension from young age, sleep apnea syndrome, pregnancy, steroid use, aortitis, etc. [22] [23] [24] [25] [26] [27] In the present study, 3 cases of aortitis were observed among the first 129 patients before exclusion of some patients. Among the 29 probands in the non-definite MFS group, 3 obstructive sleep apnea cases including 1 with ACTA2 mutations, and 1 pregnancy with ACTA2 mutations, were found. Therefore, among the 29 probands in the non-definite MFS group, there are only 2 probands with aortic disease in young age whose aortic disease might be caused by acquired factors alone. Therefore, 12 probands had genetic mutations and/or acquired factors, and aortic disease in young age in 17 probands was still inexplicable through consideration of either genetic mutations or acquired factors.
Patients with MFS often develop aortic disease such as aortic dissection or AAE in young age. MFS is characterized by phenotypic abnormalities of the skeletal, ocular, and cardiovascular systems. Especially, skeletal abnormalities such as tall stature with long extremities are indicative of MFS. However, if young patients with aortic disease did not have MFS, we could not determine the cause of their aortic disease, because the characteristic features were often not observed in the patients with disorders other than MFS. The present study clearly showed that not only physical examination but also genetic study is needed to give a proper diagnosis, especially in young patients with aortic disease without MFS.
Some limitations of the present study must be taken into account. First, COL3A1, MYH11, SLC2A10, and ACTA2 mutations were not examined for all 80 probands. We studied these mutations only in a maximum of 26 probands without FBN1, TGFBR1, and TGFBR2 mutations. We have identified simultaneous two-gene mutations of FBN1 and TGFBR2 in one proband, although such double mutations seem to be rather rare. Therefore, we suspect the incidence of ACTA2 mutations may be close to 4 out of 80 in the present study. Although we could not determine the exact incidence of the mutations, it is important to note that some patients with ACTA2 mutations can be found in the patient population with aortic disease in young age. Second, we only showed the general characteristics in young patients with aortic disease without MFS. The presentation of the non-definite MFS could be heterogeneous. They may consist of various patients including patients with unknown genetic mutations, those with unknown acquired factors, etc. However, the present study showed that the non-definite MFS patients with aortic disease at a young age possess only a few obvious characteristic features, and it is difficult for us to discriminate them from normal individuals. Third, the method used to search genetic mutations in the present study might not capture all the causative mutations.
In conclusion, genetic mutations other than FBN1 mutations were found in the non-definite MFS group with aortic disease in young age, and they accounted for one-third of all causes of aortic disease. If the etiology of aortic disease is not clear, we recommend genetic analysis with ethical considerations because these patients do not often exhibit characteristic features of MFS.
